Pyxis Oncology is trading 10.04% lower at $2.02 on October 6, 2026, with no clearly established direct catalyst in available evidence. - No new company-specific announcement explaining the intraday decline was identified. - XBI was down 2.50%, suggesting biotech-sector weakness as a possible backdrop, while the broader U.S. market was higher. - The latest major company news was the October 2 closing of a public offering that brought in about $110 million upfront, with additional potential proceeds tied to warrants. This is prior context, not a confirmed cause.